SCHEMBL17025409

SCHEMBL17025409

CCCCN1CCO[Sn]2(OCC1)OCCN(CCCC)CCO2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 4/20 0.43
MAPK1 P28482 2/20 0.43
ALDH1A1 P00352 1/20 0.43
CYP1A2 P05177 1/20 0.43
CHRM2 P08172 1/20 0.43
CHRM1 P11229 1/20 0.43
HTR2A P28223 1/20 0.43
SCN1A P35498 1/20 0.43
HTR2B P41595 1/20 0.43
KCNH2 Q12809 1/20 0.43
SCN2A Q99250 1/20 0.43
SCN3A Q9NY46 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
USP2 O75604 1/20 0.42
LMNA P02545 1/20 0.42
GNAI3 P08754 3/20 0.39
GNAO1 P09471 3/20 0.39
GNAI1 P63096 3/20 0.39
KEAP1 Q14145 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19474886 0.92 GNAO1 (0.50) SIGMAR1MAPK1ALDH1A1CYP1A2CHRM2
SCHEMBL25373345 0.81 MAPK1 (0.38) SIGMAR1MAPK1ALDH1A1CYP1A2CHRM2
SCHEMBL25376405 0.81 SIGMAR1 (0.44) SIGMAR1MAPK1ALDH1A1CYP1A2CHRM2
SCHEMBL84935 0.79 ALDH1A1 (0.61) SIGMAR1MAPK1ALDH1A1CYP1A2CHRM2
SCHEMBL25372634 0.79 SIGMAR1 (0.45) SIGMAR1MAPK1ALDH1A1CYP1A2CHRM2
SCHEMBL25374705 0.79 MAPK1 (0.36) SIGMAR1MAPK1ALDH1A1CYP1A2CHRM2
SCHEMBL25372404 0.77 MAPK1 (0.35) SIGMAR1MAPK1ALDH1A1CYP1A2CHRM2
Bromide SCHEMBL27075773 0.77 ALDH1A1 (0.59) SIGMAR1MAPK1ALDH1A1CYP1A2CHRM2
Hydrochloric Acid SCHEMBL25342847 0.77 MAPK1 (0.62) SIGMAR1MAPK1ALDH1A1CYP1A2CHRM2
Ammonia Solution, Strong SCHEMBL27204552 0.77 ALDH1A1 (0.59) SIGMAR1MAPK1ALDH1A1CYP1A2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4702066-A1 USE OF THERMOLATENT CATALYST TO IMPROVE PROPERTIES OF SINGLE-LAYER POLYURETHANE COATINGS Covestro Deutschland AG (DE) 2026-03-04 EP claimed
WO-2024223201-A1 USE OF THERMOLATENT CATALYST TO IMPROVE PROPERTIES OF SINGLE-LAYER POLYURETHANE COATINGS COVESTRO DEUTSCHLAND AG (DE) 2024-10-31 WO claimed
EP-4455177-A1 USE OF THERMOLATENT CATALYST TO IMPROVE PROPERTIES OF SINGLE-LAYER POLYURETHANE COATINGS Covestro Deutschland AG (DE) 2024-10-30 EP claimed
EP-3728472-B1 MOISTURE-CURABLE COMPOSITIONS COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) 2023-11-29 EP claimed
US-11667746-B2 Moisture-curing compositions COVESTRO DEUTSCHLAND AG (DE) 2023-06-06 US claimed
US-11555088-B2 Dual cure method using Zerewitinoff-active H tin catalysts COVESTRO DEUTSCHLAND AG (DE) 2023-01-17 US claimed
CN-111479875-B Moisture-curable composition 科思创德国股份有限公司 2022-11-15 CN claimed
EP-3601398-B1 DUAL CURE METHOD USING THERMALLY LATENT TIN CATALYSTS COVESTRO DEUTSCHLAND AG (DE) 2021-04-28 EP claimed
US-20210087324-A1 DUAL CURE METHOD USING THERMALLY LATENT TIN CATALYSTS COVESTRO DEUTSCHLAND AG (DE) 2021-03-25 US claimed
US-20200392275-A1 MOISTURE-CURING COMPOSITIONS COVESTRO DEUTSCHLAND AG (DE) 2020-12-17 US claimed
EP-3728472-A1 MOISTURE-CURING COMPOSITIONS Covestro Deutschland AG (DE) 2020-10-28 EP claimed
EP-3601398-A1 DUAL CURE METHOD USING THERMALLY LATENT TIN CATALYSTS Covestro Deutschland AG (DE) 2020-02-05 EP claimed
EP-3502185-A1 MOISTURE-CURABLE COMPOSITIONS Covestro Deutschland AG (DE) 2019-06-26 EP claimed
WO-2018178025-A1 DUAL CURE METHOD USING THERMALLY LATENT TIN CATALYSTS COVESTRO DEUTSCHLAND AG (DE) 2018-10-04 WO claimed
EP-3381959-A1 DUAL CURE METHOD USING THERMALLY LATENT TIN CATALYSTS Covestro Deutschland AG (DE) 2018-10-03 EP claimed
US-12617955-B2 Additive production process with a thermoplastic radically cross-linkable construction material STRATASYS, INC. (US) 2026-05-05 US disclosed
EP-4702066-A1 USE OF THERMOLATENT CATALYST TO IMPROVE PROPERTIES OF SINGLE-LAYER POLYURETHANE COATINGS Covestro Deutschland AG (DE) 2026-03-04 EP disclosed
US-20170368723-A1 METHOD FOR PRODUCING AN OPTICAL CAST BODY HAVING A HOLOGRAPHIC OPTICAL ELEMENT, AND OPTICAL CAST BODY COVESTRO DEUTSCHLAND AG (DE) 2017-12-28 US disclosed
WO-2017182429-A1 THERMOLATENTLY CATALYSED TWO-COMPONENT SYSTEM COVESTRO DEUTSCHLAND AG (DE) 2017-10-26 WO disclosed
US-20150240024-A1 POLYISOCYANATE-POLYADDITION PRODUCTIONS BAYER MATERIALSCIENCE AG (DE) 2015-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12617955-B2 Additive production process with a thermoplastic radically cross-linkable construction material UBE2G2, MTCL3, RAD51 SIGMAR1 3943/4885MAPK1 2036/4885ALDH1A1 295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.